IDEAYA Biosciences Beheer

Beheer criteriumcontroles 1/4

De CEO IDEAYA Biosciences is Yujiro Hata, benoemd in Jun2015, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.00M, bestaande uit 10% salaris en 90% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.8% van de aandelen van het bedrijf, ter waarde € 18.64M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 6 jaar.

Belangrijke informatie

Yujiro Hata

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris	10.0%
Dienstverband CEO	9.3yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yujiro Hata's beloning veranderd ten opzichte van IDEAYA Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$154m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$6m	US$598k	-US$113m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$3m	US$570k	-US$59m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$544k	-US$50m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$2m	US$510k	-US$34m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$2m	US$457k	-US$42m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$42m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$2m	US$420k	-US$34m

Compensatie versus markt: De totale vergoeding ($USD 6.00M ) Yujiro } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 2.45M ).

Compensatie versus inkomsten: De vergoeding van Yujiro is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yujiro Hata (50 yo)

9.3yrs

Tenure

US$5,995,440

Compensatie

Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yujiro Hata	President	9.3yrs	US$6.00m	0.80% € 18.6m
Andres Briseno	Principal Accounting Officer	3.8yrs	US$1.41m	0.029% € 674.5k
Michael White	Chief Scientific Officer	2.9yrs	US$2.76m	0% € 0
Darrin Beaupre	Chief Medical Officer	1.9yrs	US$1.81m	0% € 0
Paul Barsanti	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Douglas Snyder	Senior VP & General Counsel	less than a year	geen gegevens	geen gegevens
Francine Zelaya	Vice President & Head of Human Resources	less than a year	geen gegevens	geen gegevens
Mick O'Quigley	Chief of Staff & Clinical Development	2.6yrs	geen gegevens	geen gegevens
Daniel Simon	Chief Business Officer	less than a year	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 30J wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yujiro Hata	President	9.3yrs	US$6.00m	0.80% € 18.6m
Wendy Yarno	Independent Director	4.8yrs	US$358.02k	0% € 0
Jeffrey Stein	Independent Director	9yrs	US$363.02k	0.0051% € 117.8k
Susan Kelley	Independent Director	3.7yrs	US$349.52k	0% € 0
Frank McCormick	Chair of Scientific Advisory Board	5.7yrs	geen gegevens	geen gegevens
Scott William Morrison	Independent Director	6.3yrs	US$364.52k	0% € 0
Catherine Mackey	Independent Director	2.5yrs	US$350.52k	0% € 0
Trey Ideker	Member of Scientific Advisory Board	8.4yrs	geen gegevens	geen gegevens
William Sellers	Member of Scientific Advisory Board	5.7yrs	geen gegevens	geen gegevens
Elizabeth Swisher	Member of Scientific Advisory Board	8.4yrs	geen gegevens	geen gegevens
Terry Rosen	Independent Chairman of the Board	8.8yrs	US$369.52k	0.019% € 449.5k
Malcolm Hampton	Independent Director	4.3yrs	US$349.52k	0% € 0

6.0yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 30J wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

IDEAYA Biosciences Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

Recent updates

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd